EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
Article content
NEW YORK — EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK's deep domain expertise and established platforms and services with Capgemini's advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving operational efficiency, and accelerating the time-to-market for new therapies.
Article content
A shared vision for the future of clinical R&D
Article content
Article content
By integrating advanced digital and data capabilities—including generative AI—across all phases of clinical trials, the project will support new efficiencies for pharmaceutical companies, including:
Article content
Dramatically reduce time-to-market for new therapies.
Enablement of self-learning, insight-driven trials for faster, more proactive decision-making.
Streamlined data management and trial workflows, enhancing efficiency and precision.
Significant cost reductions and boosted drug pipeline value.
Article content
'Working with Capgemini signifies our continuing efforts to expand our global capabilities towards delivering more effective and faster clinical development,'
Article content
said Dr. Shakthi Kumar, Chief Strategy & Business Officer at EDETEK.
Article content
'By bringing together our AI-driven platforms with Capgemini's leading capabilities in life science and technology, we will empower life science organizations to conduct smarter, faster, and more predictive clinical trials—ultimately improving patient outcomes at scale.'
Article content
Bringing innovation to clinical development at scale
Article content
The engagement combines EDETEK's proven technology with Capgemini's global network and deep domain knowledge to scale AI-powered clinical innovation across the pharmaceutical industry. Together, this will help make intelligent, agile, and data-driven clinical trials accessible to more life sciences organizations worldwide. In addition, Capgemini will leverage its robust engineering capabilities to help scale EDETEK's platforms globally and enable continued leadership in reliability, innovation, and performance.
Article content
'Our deep expertise in next-gen clinical development methodologies and advanced AI will expand EDETEK's R&D cloud and eClinical platform, helping its clients to unlock new levels of agility, insight, and efficiency,'
Article content
said Thorsten Rall, Global Industry Head, Life Sciences at Capgemini.
'Together, we are committed to redefining what's possible for the industry—delivering measurable value, accelerating innovation, and shaping the future of healthcare through smarter, more predictive clinical trials.'
Article content
About EDETEK, Inc.
Article content
Founded in 2009, EDETEK delivers high-quality AI-powered platforms and clinical services to over one hundred biopharma clients worldwide. With a presence across four continents, EDETEK is redefining the future of clinical development through intelligent technology.
Article content
For more information about EDETEK, please visit www.edetek.com About Capgemini Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion.
Article content
Article content
Article content
Contacts
Article content
Capgemini press contact:
Article content
Article content
Julia Zimmerman
Article content
Article content
Tel.:+1 847-922-7951
Article content
Article content
EDETEK press contact:
Article content
Article content
Wei Kong
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
7 minutes ago
- CBC
Province will spend $6.5M to keep paramedic, EMT graduates in N.B.
Social Sharing The province has announced a $6.5-million bursary program for paramedic and emergency medical technician students that train in New Brunswick and commit to working in the province. The program will be available to current and future students until March 2026. To be eligible, paramedics must sign a two-year agreement and emergency medical technicians will need to sign a one-year agreement. Students will then be reimbursed in two payments — the first when they finish school and the second when they complete their "return-of-service" agreement. Craig Dalton, the CEO of EM/ANB Inc., previously known as Ambulance New Brunswick, said the funding will address current staffing shortages and, in turn, reduce the pressure on staff. "The reality of serving today … is that doing what they do in a system that has been beset with staffing shortages is a challenge and it takes a toll," Dalton said. The funding will cover the full cost of training for 273 paramedics and 39 EMT students. Of the paramedics, 75 are currently enrolled and up to 198 would start training in the 2025-26 academic year. WATCH | Reimbursement will help work-life balance, Ambulance N.B. CEO says: Paramedic, EMT students to get tuition money back if they work in N.B. 2 hours ago Duration 2:10 New Brunswick is putting $6.5 million into a tuition reimbursement fund for paramedic and emergency medical technician students who promise to work in the province after they graduate. Health Minister John Dornan said the province is "down by about 200" staff and this recruitment effort will help create a "more comfortable working environment." "We need to have more paramedics and EMTs on the road and this initiative will help ensure there's a pipeline of trained professionals training here to help fulfil current and future vacancies," Dornan said. Dalton said staffing struggles are "like any other health-care profession." "It's been that way for five plus years. So, it's a challenge to get that very small group of talent, and this is a huge tool in our toolbox to be able to do that," he said. Dornan said the role of paramedics is evolving, and the services they provide continue to expand. "It's tougher to be a paramedic today than it was 20 years ago," said Dornan, a doctor and former Horizon Health CEO. He said paramedics are able to put tubes into people's lungs and defibrillate patients in the ambulance. He said the province is also working to allow paramedics to give "clot busters" in the ambulance to help people survive heart attacks. "The ability, the tools that paramedics can use now are way more than they were in the past and they want this, they're asking us to let them do more." In the future, he said paramedics will be "very integrated" with the province's collaborative care teams. "Sometimes a paramedic will come to your door and you might not need to go to the hospital," Dornan said. Dalton said seven additional ambulance units will be introduced across the province this year, "in areas where we are particularly stressed with the services." Ambulance New Brunswick will also work with the province to rethink how units are dispatched. "My message is the system needs to evolve as the environment evolves, and I'm confident that we're doing that," Dalton said. Rebecca Bird has been a paramedic for three years and loves her job, despite it being difficult at times. She attended the announcement in Moncton and is glad the province is helping students. She said she would've liked the same opportunity during her training. According to Medavie HealthEd's website, the 50-week primary care paramedic program costs approximately $21,000. Bird looks forward to having more staff in the province to improve the lives of current staff. "It's really going to help staff our trucks, ensure that we're getting off on time … we're going to be able to help our other colleagues with covering what needs to be covered and hopefully giving us that work-life balance that we desperately need." According to a news release from the province, the program covers training offered by Omni Life Support Training & Consulting, Medavie HealthEd, Oulton College and Collège communautaire du Nouveau-Brunswick. Dornan didn't say whether the province would renew the bursary program, but said they would "evaluate" its value.
National Post
10 minutes ago
- National Post
Updated Briefing and Discovery Schedule for CITGO Sale Hearing
Article content PEMBROKE, Bermuda — Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (' Gold Reserve ' or the ' Company ') announces that the U.S. District Court for the District of Delaware (the ' Court ') issued an order adopting the following revised schedule for briefing and discovery deadlines proposed by the Special Master given the expiration of the Topping Period on June 18, 2025 and rescheduled start date for the Sale Hearing to August 18, 2025, as previously announced here. Article content Event Deadline Deadline for the Special Master to submit his Final Recommendation July 2 Deadline to serve written discovery on the party (or parties) whose bid is selected as the Final Recommendation July 7 Opening expert reports due July 7 Deadline for the filing of any objections to the Special Master's Final Recommendation July 9 Deadline for any Competing Objector to disclose its own bid materials (such materials to be commensurate with those disclosed by the Special Master of the recommended bid) July 9 Deadline to serve written discovery on a Competing Objector July 11 Deadline to serve responses and objections for discovery requests served after the Final Recommendation July 15 Deadline to meet and confer regarding the scope of discovery to be produced in response to discovery requests served after submission of the Final Recommendation July 16 Deadline to serve witness disclosures pursuant to FRCP 26(a)(3) July 18 Deadline to notice witness depositions July 21 Deadline to serve responsive expert reports July 21 Deadline to complete document productions in response to discovery requests served before the submission of the Final Recommendation and substantially complete document productions in response to discovery requests served after the submission of the Final Recommendation July 22 Deadline to serve reply expert reports, if any July 25 Conclusion of the discovery period July 31 Deadline for the filing of responses to objections to the Special Master's Final Recommendation August 1 Deadline for the filing of replies regarding any objections to the Special Master's Final Recommendation August 8 Deadline for the filing of sur-replies to replies regarding any objections to the Special Master's Final Recommendation (only to the extent new arguments are raised in reply briefing) August 12 Deadline for the Special Master to submit Joint Status Report August 13 Deadline to disclose exhibits pursuant to FRCP 26(a)(3) August 13 Deadline to serve objections to FRCP 26(a)(3) exhibit disclosures August 15 Commencement of the Sale Hearing August 18 Article content Article content A copy of the Court's complete order can be found here. Article content A complete description of the Delaware sale proceedings can be found on the Public Access to Court Electronic Records system in Crystallex International Corporation v. Bolivarian Republic of Venezuela, 1:17-mc-00151-LPS (D. Del.) and its related proceedings. Article content This release contains 'forward-looking statements' within the meaning of applicable U.S. federal securities laws and 'forward-looking information' within the meaning of applicable Canadian provincial and territorial securities laws and state Gold Reserve's and its management's intentions, hopes, beliefs, expectations or predictions for the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. They are frequently characterized by words such as 'anticipates', 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed', 'positioned' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements contained in this press release include, but are not limited to, statements relating to any bid submitted by the Company for the purchase of the PDVH shares (the 'Bid'). Article content We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause the actual events, outcomes or results of Gold Reserve to be materially different from our estimated outcomes, results, performance, or achievements expressed or implied by those forward-looking statements, including but not limited to: the discretion of the Special Master to consider the Bid, to enter into any discussions or negotiation with respect thereto and that the Special Master may reject the Bid at any time; the Special Master may choose not to recommend a Base Bid or Final Bid to the Court; the failure of the Company to negotiate the Bid, including as a result of failing to obtain sufficient equity and/or debt financing; that Bid submitted by the Company will not be selected as the 'Base Bid' or the 'Final Recommend Bid' under the Bidding Procedures, and if selected may not close due to the Sale Process not being completed, including as a result of not obtaining necessary regulatory approval to close on the purchase of the PDVH shares, including but not limited to any necessary approvals from the U.S. Office of Foreign Asset Control ('OFAC'), the U.S. Committee on Foreign Investment in the United States, the U.S. Federal Trade Commission or the TSX Venture Exchange; failure of the Company or any other party to obtain any required shareholders approvals for, or satisfy other conditions to effect, any transaction resulting from the Bid; that the Company forfeit any cash amount deposit made due to failing to complete the Bid or otherwise; that the making of the Bid or any transaction resulting therefrom may involve unexpected costs, liabilities or delays; that, prior to or as a result of the completion of any transaction contemplated by the Bid, the business of the Company may experience significant disruptions due to transaction related uncertainty, industry conditions, tariff wars or other factors; the ability to enforce the writ of attachment granted to the Company; the timing set for various reports and/or other matters with respect to the Sale Process may not be met; the ability of the Company to otherwise participate in the Sale Process (and related costs associated therewith); the amount, if any, of proceeds associated with the Sale Process; the competing claims of other creditors of Venezuela, PDVSA and the Company, including any interest on such creditors' judgements and any priority afforded thereto; uncertainties with respect to possible settlements between Venezuela and other creditors and the impact of any such settlements on the amount of funds that may be available under the Sale Process; and the proceeds from the Sale Process may not be sufficient to satisfy the amounts outstanding under the Company's September 2014 arbitral award and/or corresponding November 15, 2015 U.S. judgement in full; and the ramifications of bankruptcy with respect to the Sale Process and/or the Company's claims, including as a result of the priority of other claims. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. For a more detailed discussion of the risk factors affecting the Company's business, see the Company's Management's Discussion & Analysis for the year ended December 31, 2024 and other reports that have been filed on SEDAR+ and are available under the Company's profile at Article content Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Gold Reserve or persons acting on its behalf are expressly qualified in their entirety by this notice. Gold Reserve disclaims any intent or obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of assumptions or factors, whether as a result of new information, future events or otherwise, subject to its disclosure obligations under applicable rules promulgated by applicable Canadian provincial and territorial securities laws. Article content Article content Article content Article content
Globe and Mail
11 minutes ago
- Globe and Mail
GME Earnings: GameStop Reports Mixed Financial Results and 4,710 Bitcoin
GameStop's (GME) share price is down about 5% after the video game retailer reported mixed first-quarter financial results. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The Texas-based company announced earnings per share (EPS) of $0.09, which topped the $0.04 consensus expectation of analysts. However, revenue for the quarter came in at $732.4 million, which was below the consensus Wall Street estimate of $754.2 million. The company also reported an improved operating margin of -1.5%, which was up from -5.7% in the same quarter of 2024. GameStop's free cash flow at the end of the quarter totaled $189.6 million, which was a big improvement from negative -$114.7 million a year earlier. GameStop's profitability. Source: Main Street Data Bitcoin Purchases Along with its financial results, GameStop disclosed that it bought 4,710 Bitcoins (BTC) between May 3 and June 10 of this year. It's not known what the average purchase price of the Bitcoin was. However, GameStop's BTC holdings are currently worth $516.6 million based on the current price of Bitcoin. GameStop announced previously that it planned to begin buying and holding cryptocurrencies, adopting a similar playbook to that of software developer turned serial BTC acquirer Strategy (MSTR). GameStop has said it plans to use its excess cash to make investments in risk assets such as crypto and stocks. The company made its first Bitcoin investment in May of this year. Is GME Stock a Buy? Currently, only one Wall Street analysts offers a rating and price target on GME stock. So instead, we'll look at the stock's three-month performance. As one can see in the chart below, GameStop's share price has gained 33% over the last 12 weeks.
